このページの翻訳は実験的なもので、現在開発中です。お待ちしております！

MiMedx Group 過去の業績

過去基準チェック /36

MiMedx Groupは、平均年間42.2%の収益成長を遂げていますが、 Biotechs業界の収益は、年間成長しています。収益は、平均年間15.5% 0.3%収益成長率で減少しています。 MiMedx Groupの自己資本利益率は50.4%であり、純利益率は20.5%です。

主要情報

42.2%

収益成長率

41.9%

EPS成長率

Biotechs 業界の成長	17.0%
収益成長率	-0.3%
株主資本利益率	50.4%
ネット・マージン	20.5%
前回の決算情報	31 Mar 2024

Recent updates

MiMedx Group, Inc.'s (NASDAQ:MDXG) Shares Bounce 27% But Its Business Still Trails The Industry

May 21

We Think MiMedx Group (NASDAQ:MDXG) Can Stay On Top Of Its Debt

May 14

Improved Revenues Required Before MiMedx Group, Inc. (NASDAQ:MDXG) Shares Find Their Feet

Mar 27

We Think MiMedx Group (NASDAQ:MDXG) Can Stay On Top Of Its Debt

Jan 05

MiMedx Group, Inc. (NASDAQ:MDXG) Stock Catapults 27% Though Its Price And Business Still Lag The Industry

Dec 18

収支内訳

MiMedx Group の稼ぎ方とお金の使い方。LTMベースの直近の報告された収益に基づく。

収益と収入の歴史

NasdaqCM:MDXG 収益、費用、利益 ( )USD Millions
日付	収益	収益	G+A経費	研究開発費
31 Mar 24	335	68	216	12
31 Dec 23	321	56	216	13
30 Sep 23	309	11	215	8
30 Jun 23	295	-6	219	11
31 Mar 23	281	-18	225	10
31 Dec 22	268	-27	221	13
30 Sep 22	261	-34	216	22
30 Jun 22	256	-28	209	20
31 Mar 22	258	-19	202	19
31 Dec 21	242	-18	199	10
30 Sep 21	260	-35	223	16
30 Jun 21	261	-83	233	15
31 Mar 21	246	-88	231	13
31 Dec 20	248	-83	240	12
30 Sep 20	256	-73	212	11
30 Jun 20	281	-8	210	10
31 Mar 20	294	-17	233	11
31 Dec 19	299	-26	265	11
30 Sep 19	315	-54	270	13
30 Jun 19	314	-67	287	14
31 Mar 19	342	-48	295	15
31 Dec 18	359	-30	295	16
30 Sep 18	354	41	275	15
30 Jun 18	352	59	260	16
31 Mar 18	333	65	235	17
31 Dec 17	321	65	220	18
30 Sep 17	303	35	216	18
30 Jun 17	283	21	205	15
31 Mar 17	264	15	192	14
31 Dec 16	222	0	172	14
30 Sep 16	227	20	168	11
30 Jun 16	212	23	154	10
31 Mar 16	200	27	144	9
31 Dec 15	187	29	133	8
30 Sep 15	175	20	126	8
30 Jun 15	160	17	115	8
31 Mar 15	139	11	104	7
31 Dec 14	118	6	90	7
30 Sep 14	97	1	75	7
30 Jun 14	79	-3	64	6
31 Mar 14	67	-3	54	5
31 Dec 13	59	-4	46	5
30 Sep 13	52	-4	40	5
30 Jun 13	44	-8	33	4

質の高い収益: MDXG 非現金収入のレベルが高いです。

利益率の向上: MDXG過去に利益を上げました。

フリー・キャッシュフローと収益の比較

過去の収益成長分析

収益動向: MDXG過去 5 年間で収益を上げており、収益は年間42.2%増加しています。

成長の加速: MDXGは昨年収益を上げたため、収益成長率を 5 年間の平均と比較することは困難です。

収益対業界: MDXG昨年収益を上げたため、昨年の収益成長をBiotechs業界 ( -14.4% ) と比較することは困難です。

株主資本利益率

高いROE: MDXGの自己資本利益率 ( 50.4% ) は傑出していると考えられます。

MiMedx Group 過去の業績

過去 基準チェック /36

主要情報

最近の業績更新

First quarter 2024 earnings: EPS and revenues exceed analyst expectations

MiMedx Group, Inc. to Report Q1, 2024 Results on Apr 30, 2024

Full year 2023 earnings: EPS exceeds analyst expectations

MiMedx Group, Inc. to Report Q4, 2023 Results on Feb 28, 2024

Third quarter 2023 earnings: EPS and revenues exceed analyst expectations

MiMedx Group, Inc. to Report Q3, 2023 Results on Oct 30, 2023

Recent updates

MiMedx Group, Inc.'s (NASDAQ:MDXG) Shares Bounce 27% But Its Business Still Trails The Industry

We Think MiMedx Group (NASDAQ:MDXG) Can Stay On Top Of Its Debt

Investor sentiment improves as stock rises 18%

First quarter 2024 earnings: EPS and revenues exceed analyst expectations

MiMedx Group, Inc., Annual General Meeting, Jun 05, 2024

MiMedx Group, Inc. to Report Q1, 2024 Results on Apr 30, 2024

MiMedx Group, Inc. Provides Update on AXIOFILL Request for Designation (RFD) from FDA

Improved Revenues Required Before MiMedx Group, Inc. (NASDAQ:MDXG) Shares Find Their Feet

Insider recently sold US$162k worth of stock

Mimedx Introduces E-Commerce and Account Management Platform

MiMedx Group, Inc. Announces Appointment of New Independent Directors

Full year 2023 earnings: EPS exceeds analyst expectations

New minor risk - Insider selling

Insider recently sold US$250k worth of stock

MiMedx Group, Inc. to Report Q4, 2023 Results on Feb 28, 2024

We Think MiMedx Group (NASDAQ:MDXG) Can Stay On Top Of Its Debt

Forecast breakeven date pushed back to 2024

MiMedx Group, Inc. (NASDAQ:MDXG) Stock Catapults 27% Though Its Price And Business Still Lag The Industry

Third quarter 2023 earnings: EPS and revenues exceed analyst expectations

Forecast breakeven date pushed back to 2024

MiMedx Group, Inc. to Report Q3, 2023 Results on Oct 30, 2023

Mimedx Group, Inc. Announces Launch of Epieffect

Mimedx Group, Inc. Announces Retirement of Mr. William Phelan as Chief Accounting Officer

Is MiMedx Group (NASDAQ:MDXG) Using Debt In A Risky Way?

MiMedx Group, Inc. Provides Earnings Guidance for the Fiscal Year 2023

Second quarter 2023 earnings released: EPS: US$0.01 (vs US$0.11 loss in 2Q 2022)

Price target increased by 8.0% to US$10.17

Forecast breakeven date moved forward to 2023

MiMedx Group, Inc. Announces Chief Financial Officer Changes

Consensus EPS estimates upgraded to US$0.10 loss

Price target decreased by 9.3% to US$9.29

Insider recently sold US$84k worth of stock

Insider notifies of intention to sell stock

MiMedx Group, Inc., Annual General Meeting, Jun 13, 2023

Insider recently sold US$276k worth of stock

Insider notifies of intention to sell stock

First quarter 2023 earnings: EPS and revenues exceed analyst expectations

Does MiMedx Group (NASDAQ:MDXG) Have A Healthy Balance Sheet?

Insider notifies of intention to sell stock

Chief Financial Officer recently sold US$85k worth of stock

Chief Financial Officer notifies of intention to sell stock

MiMedx Group, Inc. Announces Chief Executive Officer Changes

MiMedx Group, Inc. to Report Q4, 2022 Results on Mar 01, 2023

MiMedx Group, Inc. Appoints Ricci S. Whitlow as Chief Operating Officer

Health Check: How Prudently Does MiMedx Group (NASDAQ:MDXG) Use Debt?

MiMedx Group, Inc. Announces the Resignation of Rohit Kashyap as President, Wound Care and Surgical, Effective January 3, 2023

Price target decreased to US$10.25

High number of new directors

Third quarter 2022 earnings: EPS and revenues exceed analyst expectations

MiMedx Group, Inc. Provides Net Sales Guidance for the Fourth Quarter and Full Year 2022

MiMedx Group, Inc. to Report Q3, 2022 Results on Nov 02, 2022

Price target decreased to US$10.25

Mimedx Group, Inc. Announces Management Changes

High number of new directors

MiMedx Group, Inc. Announces Launch of AXIOFILL

MiMedx Group, Inc. Announces Launch of AMNIOEFFECT™

Insider recently sold US$94k worth of stock

MIMEDX EPIFIX® Receives Reimbursement Approval in Japan

MiMedx gets Japanese reimbursement approval for its tissue allograft EPIFIX

Consensus EPS estimates fall by 12%

MiMedx Group, Inc. Provides Sales Guidance for the Year Ending December 31, 2022

MiMedx Group expects AWC full-year sales in low end of 11%-14% growth range

Insider recently sold US$71k worth of stock

Consensus forecasts updated

Second quarter 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

MiMedx Group, Inc. Reaffirms Revenue Guidance for 2022

High number of new directors

MiMedx Group, Inc. Forms Regenerative Medicine Scientific Advisory Board Comprised of Renowned Industry and Academic Experts

MiMedx Group, Inc. to Report Q2, 2022 Results on Aug 02, 2022

過去基準チェック /36